It is a report testing AP outside of the hospital. Reader digest version: Kids had fewer lows and better control with AP.
New PODDs in weeks
For our existing customers, we will begin the transition from the original product to the new OmniPod in the next few weeks.
... we expect to file in the coming months a submission requesting 510(k) clearance for a PDM integrated with LifeScan Verio blood glucose meter. We are hopeful that this new PDM will be commercially available in 2013
... one of the blocking things that was out there was our whole insulin on-board calculation and not to bore everybody with the kind of arcane way we did it, but we thought we had kind of a better mouse trap. It wasn't the way the market leader did it. So this product basically put it in line with the way the market leader did it
.... Finally, in January, we signed an agreement with a new continuous glucose monitoring partner. The agreement calls for both parties to continue development work already underway towards the ultimate goal of an OmniPod integrated with a CGM sensor.In Q& A re the name of the sensor partner,
... we have with the company until we get to the point where we think we have a final version, a commercial version, we agreed not to give involved in disclosing that
.... we tested on pigs, so far so good. Sometime next year we'd like to be doing it on people. And we'd like to be doing it on people not as a stand-alone sensor, but in our integrated format. So the big engineering hurdles/opportunities for us is how do we insert this within the framework of the product we have? And how close can it be to the insulin delivery? And the third one is -- and we've tested this a lot now, but we still have to go through in testing it in final is can the sensor withstand ETO sterilization.There is more on the CGM partnership in the Q&A part the call. Hop over to Seeking Alpha if you are interested.
Conference CallInsulet will host a conference call on Wednesday, February 27, 2013 at 5:00PM Eastern time to discuss the Company's fourth quarter and full year 2012 results and present information concerning its business, strategies and outlook. To listen to the conference call, please dial (877) 831-5664 for domestic callers and (832) 412-1780 for international callers. The passcode is 98386780. A replay of the conference call will be available two hours after the start of the call through March 27, 2013 by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), passcode 98386780. An online archive of the conference call will also be available by accessing the Investor Information section of the company's website at http://investors.insulet.com.
I am part of the Diabetes Advocates. A friend there encouraged joining National Eating Disorders Awareness Week to share views on diabetes and eating disorders. I am happy to. You can find more links from other DA members here. This post a rerun of a previously blogged post. In it I share some thoughts on parenting contributing eating problems.
National Eating Disorders Awareness Week is, February 24th – March 2nd, this year's theme is, Everybody Knows Somebody.
(OK not much of an artist)
The study’s findings do not mean that mice are useless models for all human diseases. But, its authors said, they do raise troubling questions about diseases like the ones in the study that involve the immune system, including cancer and heart disease.
The Pearl insulin pump is designed to make living every day with an insulin pump, easier.
Filling a pump reservoir is an outdated process in today’s world. So we designed our insulin pump around a pre-filled insulin cartridge, a simple-to-use interface, a pump that primes itself as you assemble it, and occlusion detection designed to identify occlusions earlier. Not just fancier, but really, less work.
The Pearl insulin pump has a durable controller and a replaceable pump body that, once assembled, functions as a "traditional" insulin pump. Just insert the prefilled cartridge into the replaceable pump body that simply clicks together with the controller, and off you go.
Half the work, half the time.
New Children's Electronic Health Record Format Announced
A new database developed by the Agency for Healthcare Research and Quality with support from the Centers for Medicare and Medicaid Services can help software developers create better Electronic Health Records (EHRs) for the care of children. The children’s EHR format establishes a blueprint for EHRs to better meet the needs of health care providers and pediatric patients by combining best-practices in clinical care, information technology, and insights from experts in children’s health. Since few EHRs have been created with children’s needs in mind, gaps in functionality, data elements and other areas tend to occur. The format guides EHR developers in understanding the requirements for functionality, data standards, usability and interoperability of an EHR system to more optimally support the provision of health care to children – especially those enrolled in Medicaid or the Children’s Health Insurance Program (CHIP). The format is readily accessible and adoptable by EHR developers for use during product development or enhancement.
In addition to providing guidance to developers, the format can provide guidance for EHR system purchasers and policy makers. For example, policy makers and purchasers can use the requirements when assessing functionality of EHRs. For more information or to access the format, select:http://healthit.ahrq.gov/
Tandem Diabetes Care Acquires Select Patents and Patent Applications from Smiths Medical
SAN DIEGO, Feb. 1, 2013 /PRNewswire/ -- Tandem Diabetes Care, Inc. ("Tandem") announced today that it has acquired ownership from Smiths Medical ASD, Inc. of over 23 U.S. patents and patent applications relating to the treatment of diabetes. As part of this transaction, Tandem has also obtained a license to 28 other U.S. patents and patent applications owned by Smiths Medical. This license affords Tandem exclusive access to technologies useful for future product development in the field of ambulatory infusion pumps and related software and accessories for the treatment of diabetes. These patents and patent applications complement Tandem's growing portfolio of intellectual property related to the company's novel technologies PR Newswire (http://s.tt/1zfjY)